Get the Stockscreener App
2.115
1.63%
-0.035
Proqr Therapeutics N V stock is traded at $2.115, with a volume of 260.61K.
It is down -1.63% in the last 24 hours and down -20.19% over the past month.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
See More
Previous Close:
$2.15
Open:
$2.14
24h Volume:
260.61K
Relative Volume:
0.51
Market Cap:
$172.72M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.5834
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-2.08%
1M Performance:
-20.19%
6M Performance:
+9.59%
1Y Performance:
-2.53%
1-Day Range:
$2.02
$2.21
1-Week Range:
$1.95
$2.21
52-Week Range:
$1.61
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.115 | 172.72M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com
Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com
ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World
ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St
ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World
Leiden-based biotech company ProQR bags €7.7M - Silicon Canals
ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com
JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat
ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance
RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News
ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa
ProQR secures $9.1M for Rett syndrome trial - Investing.com India
ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire
ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan
ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times
ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities - Yahoo Finance
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com - Defense World
OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics NV (MEX:PRQR) Earnings Yield % : N/A% (As of Nov. 21, 2024) - GuruFocus.com
RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ProQR: Q3 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):